Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2012

Global Markets Direct, July 2012, Pages: 105

Respiratory Syncytial Virus (RSV) Infections – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2012', provides an overview of the Respiratory Syncytial Virus (RSV) Infections therapeutic pipeline. This report provides information on the therapeutic development for Respiratory Syncytial Virus (RSV) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Respiratory Syncytial Virus (RSV) Infections. 'Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Respiratory Syncytial Virus (RSV) Infections.
- A review of the Respiratory Syncytial Virus (RSV) Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Respiratory Syncytial Virus (RSV) Infections pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Respiratory Syncytial Virus (RSV) Infections.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Respiratory Syncytial Virus (RSV) Infections pipeline depth and focus of Respiratory Syncytial Virus (RSV) Infections therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Respiratory Syncytial Virus (RSV) Infections Therapeutic Products under Development, Key Players in Respiratory Syncytial Virus (RSV) Infections Therapeutics, Respiratory Syncytial Virus (RSV) Infections Pipeline Overview, Respiratory Syncytial Virus (RSV) Infections Pipeline, Respiratory Syncytial Virus (RSV) Infections Pipeline Assessment

2
List of Tables 7
List of Figures 8
Introduction 9
REPORT COVERAGE 9
Respiratory Syncytial Virus (RSV) Infections Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Respiratory Syncytial Virus (RSV) Infections 11
Respiratory Syncytial Virus (RSV) Infections Therapeutics under Development by Companies 13
Mid Clinical Stage Products 16
Comparative Analysis 16
Early Clinical Stage Products 17
Comparative Analysis 17
Discovery and Pre-Clinical Stage Products 18
Comparative Analysis 18
Respiratory Syncytial Virus (RSV) Infections Therapeutics – Products under Development by Companies 19
Companies Involved in Respiratory Syncytial Virus (RSV) Infections Therapeutics Development 20
Johnson & Johnson 20
AstraZeneca PLC 21
Bavarian Nordic A/S 22
MedImmune LLC 23
GenVec, Inc. 24
Ablynx 25
Symphogen A/S 26
Celltrion, Inc. 27
Novavax, Inc. 28
Crucell N.V. 29
Mymetics Corporation 30
Pevion Biotech Ltd 31
Alnylam Pharmaceuticals, Inc 32
Summit Corporation plc 33
Functional Genetics, Inc. 34
LigoCyte Pharmaceuticals, Inc. 35
Mucosis B.V. 36
Okairos 37
AlphaVax, Inc. 38
Romark Laboratories, L.C. 39
REPLICor Inc. 40
NanoBio Corporation 41
iBio, Inc. 42
Sirnaomics, Inc. 43
Merus B.V. 44
MicroDose Therapeutx, Inc. 45
Clarassance, Inc. 46
Respiratory Syncytial Virus (RSV) Infections – Therapeutics Assessment 47
Assessment by Monotherapy Products 47
Assessment by Route of Administration 48
Assessment by Molecule Type 50
Drug Profiles 52
ALN-RSV01 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
MEDI-534 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
MEDI-559 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
MEDI-557 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Sym003 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
MVA-BN RSV - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
Vaccine For RSV - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
MDT-637 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
REP 9AC - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
REP 9 - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
RSV Vaccine - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
RI-001 - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
ALX-0171 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
PEV4 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
Respiratory Syncytial Virus (RSV) Vaccine - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
RSV VLP Vaccine - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
RV-568 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
RSV Vaccine - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Antiviral Program - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
RSV Vaccine - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Drug For RSV Infection - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
SLP1001 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
SLP0904 - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Respiratory Syncytial Virus Vaccine - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
New Thiazolides - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
RSV Vaccine - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
STP902 - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
Drug For Infectious Disease - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
RSV Vaccine - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
SynGEM - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
FGI-110 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
CG100 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
Respiratory Syncytial Virus (RSV) Infections Therapeutics – Drug Profile Updates 89
Respiratory Syncytial Virus (RSV) Infections Therapeutics – Discontinued Products 95
Respiratory Syncytial Virus (RSV) Infections Therapeutics - Dormant Products 96
Respiratory Syncytial Virus (RSV) Infections – Product Development Milestones 97
Featured News & Press Releases 97
Jul 05, 2012: Novavax Reports On Progress With RSV Vaccine At New International Conference On Modern Vaccines 97
Jun 27, 2012: Novavax To Review RSV Program At New International Conference On Modern Vaccines 98
May 30, 2012: Alnylam Announces Top-Line Results Of Phase IIb Clinical Trial Of ALN-RSV01 For Treatment Of Respiratory Syncytial Virus Infection 98
May 03, 2012: GenVec Receives Grant For RSV Vaccine Program 100
Apr 24, 2012: MicroDose Concludes Second Phase I Study Of MDT-637 For Treatment Of Respiratory Syncytial Virus Infection 100
Mar 23, 2012: GenVec Presents Data On Respiratory Syncytial Virus Vaccine Program At Keystone Symposium On Viral Immunity And Host Gene Influence 101
Mar 22, 2012: NOVAVAX To Present Results From Phase I RSV Study At XIV International Symposium On Respiratory Viral Infections 101
Dec 13, 2011: Ablynx Initiates Phase I Study With ALX-0171 For Treatment Of Respiratory Syncytial Virus 102
Dec 13, 2011: Ablynx Initiates Phase I Study With ALX-0171 For Treatment Of Respiratory Syncytial Virus 102
Nov 29, 2011: Alnylam Completes Enrollment In Phase IIb Study Of ALN-RSV01 For Treatment Of Respiratory Syncytial Virus Infection 102
Appendix 104
Methodology 104
Coverage 104
Secondary Research 104
Primary Research 104
Expert Panel Validation 104
Contact Us 105
Disclaimer 105

List of Tables
Number of Products Under Development for Respiratory Syncytial Virus (RSV) Infections, H2 2012 11
Products under Development for Respiratory Syncytial Virus (RSV) Infections – Comparative Analysis, H2 2012 12
Number of Products under Development by Companies, H2 2012 14
Number of Products under Development by Companies, H2 2012 (Contd..1) 15
Comparative Analysis by Mid Clinical Stage Development, H2 2012 16
Comparative Analysis by Early Clinical Stage Development, H2 2012 17
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 18
Products under Development by Companies, H2 2012 19
Johnson & Johnson, H2 2012 20
AstraZeneca PLC, H2 2012 21
Bavarian Nordic A/S, H2 2012 22
MedImmune LLC, H2 2012 23
GenVec, Inc., H2 2012 24
Ablynx, H2 2012 25
Symphogen A/S, H2 2012 26
Celltrion, Inc., H2 2012 27
Novavax, Inc., H2 2012 28
Crucell N.V., H2 2012 29
Mymetics Corporation, H2 2012 30
Pevion Biotech Ltd, H2 2012 31
Alnylam Pharmaceuticals, Inc, H2 2012 32
Summit Corporation plc, H2 2012 33
Functional Genetics, Inc., H2 2012 34
LigoCyte Pharmaceuticals, Inc., H2 2012 35
Mucosis B.V., H2 2012 36
Okairos, H2 2012 37
AlphaVax, Inc., H2 2012 38
Romark Laboratories, L.C., H2 2012 39
REPLICor Inc., H2 2012 40
NanoBio Corporation, H2 2012 41
iBio, Inc., H2 2012 42
Sirnaomics, Inc., H2 2012 43
Merus B.V., H2 2012 44
MicroDose Therapeutx, Inc., H2 2012 45
Clarassance, Inc., H2 2012 46
Assessment by Monotherapy Products, H2 2012 47
Assessment by Stage and Route of Administration, H2 2012 49
Assessment by Stage and Molecule Type, H2 2012 51
Respiratory Syncytial Virus (RSV) Infections Therapeutics – Drug Profile Updates 89
Respiratory Syncytial Virus (RSV) Infections Therapeutics – Discontinued Products 95
Respiratory Syncytial Virus (RSV) Infections Therapeutics – Dormant Products 96

List of Figures
Number of Products under Development for Respiratory Syncytial Virus (RSV) Infections, H2 2012 11
Products under Development for Respiratory Syncytial Virus (RSV) Infections – Comparative Analysis, H2 2012 12
Products under Development by Companies, H2 2012 13
Mid Clinical Stage Products, H2 2012 16
Early Clinical Stage Products, H2 2012 17
Discovery and Pre-Clinical Stage Products, H2 2012 18
Assessment by Monotherapy Products, H2 2012 47
Assessment by Route of Administration, H2 2012 48
Assessment by Stage and Route of Administration, H2 2012 49
Assessment by Molecule Type, H2 2012 50
Assessment by Stage and Molecule Type, H2 2012 51

Customers who bought this item also bought

• Respiratory Syncytial Virus (RSV) Infections - Pipeline Review, H1 2012
• Competitor Analysis: RSV Vaccines and Therapeutics
• Respiratory Syncytial Virus (Rsv) Infection - Pipeline Review, Q3 2011
• Other Viral Infections - Pipeline Review, H2 2012
• Bacterial Respiratory Tract Infections - Pipeline Review, H2 2012
• Influenza A Infections - Pipeline Review, H2 2012
• Stakeholder Opinions: Respiratory viral infections - Respiratory syncytial virus, parainfluenza virus and human metapneumovirus as promising new targets
• Rotavirus Infections - Pipeline Review, H2 2012
• Upper Respiratory Tract Disorders - Pipeline Review, H2 2012
• Bordetella Pertussis Infections - Pipeline Review, H2 2012